Literature DB >> 356543

The choice of animal tumors for experimental studies of cancer therapy.

H B Hewitt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356543     DOI: 10.1016/s0065-230x(08)60932-x

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  28 in total

Review 1.  The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

Authors:  S D Voss; G Weil-Hillman; J A Hank; J A Sosman; P M Sondel
Journal:  Bull N Y Acad Med       Date:  1989-01

Review 2.  Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules.

Authors:  D Naor
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Interferons as antitumor agents.

Authors:  H Kirchner
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 4.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Logistics of tumor immunology.

Authors:  H Kirchner
Journal:  Klin Wochenschr       Date:  1982-01-04

Review 6.  Manipulation of host resistance in cancer therapy.

Authors:  R W Baldwin
Journal:  Springer Semin Immunopathol       Date:  1982

Review 7.  Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

Authors:  J W Kreider; G L Bartlett; B L Butkiewicz
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Organ vascularity and metastatic frequency.

Authors:  L Weiss; K Haydock; J W Pickren; W W Lane
Journal:  Am J Pathol       Date:  1980-10       Impact factor: 4.307

Review 9.  Tumor hypoxia: its impact on cancer therapy.

Authors:  J E Moulder; S Rockwell
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

10.  Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses.

Authors:  B Y Klein; S Frenkel; D Naor
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.